Kidney Cancer section

Kidney Cancer News & Features

Axitinib Plus Pembrolizumab Shows Promise in Treatment-Naïve Advanced RCC

Axitinib Plus Pembrolizumab Shows Promise in Treatment-Naïve Advanced RCC

Nonrandomized trial demonstrates tolerability and antitumor activity of a PD-1 checkpoint inhibitor plus a VEGF-TKI in patients with treatment-naïve advanced RCC.

Sex, Age Associated With Mortality Risk in Renal Cell Cancer Treated With VEGF-TKIs

Sex, Age Associated With Mortality Risk in Renal Cell Cancer Treated With VEGF-TKIs

Phase 3 study sought to assess the associations between adjuvant therapy with VEGF-tyrosine kinase inhibitors (TKIs) and benefit, sex, and age in patients with resected renal cell cancer.

Antibiotics May Reduce Treatment-Related Issues in Renal Cell Carcinoma

Antibiotics May Reduce Treatment-Related Issues in Renal Cell Carcinoma

Researchers evaluated the effect of antibiotics on treatment delays, interruptions, and dose reductions in patients with mRCC treated with a first-line VEGF-TKI and presented their results at the 2018 Genitourinary Cancers Symposium.

FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC

FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC

Combination therapy with lenvatinib and pembrolizumab is granted Breakthrough Therapy Designation for the treatment of advanced or metastatic renal cell carcinoma (RCC).

Patients Report Significant Fatigue with Sorafenib, Sunitinib in Renal Cell Carcinoma

Patients Report Significant Fatigue with Sorafenib, Sunitinib in Renal Cell Carcinoma

Although TKIs improve outcomes, they are still associated with toxicities common with cancer therapies, such as fatigue.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs